Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) rose 6.2% during trading on Monday . The stock traded as high as $27.03 and last traded at $27.59. Approximately 42,876 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 547,786 shares. The stock had previously closed at $25.97.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. Citigroup began coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 target price for the company. HC Wainwright lifted their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Stephens reaffirmed an "overweight" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, Leerink Partners reissued an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.36.
Get Our Latest Analysis on KYMR
Kymera Therapeutics Price Performance
The company has a market cap of $2.15 billion, a P/E ratio of -14.19 and a beta of 2.22. The stock has a fifty day moving average price of $29.96 and a two-hundred day moving average price of $38.67.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million during the quarter, compared to analysts' expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,659 shares of company stock worth $324,567. 15.82% of the stock is owned by insiders.
Institutional Investors Weigh In On Kymera Therapeutics
Large investors have recently made changes to their positions in the business. Blue Trust Inc. increased its holdings in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after buying an additional 270 shares during the last quarter. State of Wyoming bought a new position in shares of Kymera Therapeutics during the 4th quarter valued at approximately $45,000. GF Fund Management CO. LTD. purchased a new stake in shares of Kymera Therapeutics during the 4th quarter worth approximately $55,000. KBC Group NV raised its holdings in shares of Kymera Therapeutics by 15.2% in the 1st quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after purchasing an additional 328 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Kymera Therapeutics by 3,851.5% in the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock valued at $183,000 after purchasing an additional 6,509 shares during the last quarter.
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Further Reading
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
